TGTX Soars on Buyout Rumors, but Director Sold Weeks Prior
TG Therapeutics (TGTX) stock surged to a 3.5-month high on acquisition rumors. However, a director sold shares five weeks earlier and no SEC filing corroborates any bid, signaling potential insider sk
TGTX Best Day in 3.5 Months on Fresh Buyout Rumors
NEW YORK, October 15 —
Buyout speculation has lifted TG Therapeutics, Inc. (TGTX) to its best single-session gain in 3.5 months, but the only insider transaction in the past 90 days is a director's open-market sale at $54.96 five weeks before the rumors returned, and no SEC filing corroborates any acquisition approach.
- Director Charney sold 5,000 shares at market on September 10; no TGTX insider purchased shares in the 90-day period.
- Five-year data: BRIUMVI cut disability progression to 9.4% versus 17.9% for rival ofatumumab.
- Short interest at 28.9% of float; 74.7% institutional ownership; any credible bid could trigger a short-covering event.
BRIUMVI's Half-Rate Advantage
TG Therapeutics, Inc. (TGTX) is built around one commercial product: BRIUMVI, an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. The clinical case for acquisition value sharpened with a five-year analysis showing disability progression at 9.4% for BRIUMVI patients versus 17.9% for ofatumumab, a competing anti-CD20 agent used as the trial comparator. That roughly two-to-one advantage on a hard endpoint gives a prospective acquirer something concrete to underwrite. Trailing revenue reached $800 million on 70.3% growth at 82.4% gross margins; run the acquisition math through the DCF calculator to assess what a premium bid would require.
The Director Who Sold Before the Buzz
The contradicting signal came from inside the company. Director Laurence N. Charney executed an open-market sale of 5,000 shares at $54.96 on September 10, 2026, five weeks before today's acquisition speculation, generating $274,800 in proceeds. Over the 90-day window, no TGTX insider made a single open-market purchase. An executive acting on knowledge of imminent deal activity would face legal constraints on selling at market prices; the open-market nature of Charney's transaction suggests he was not acting on such knowledge. No SEC filing in the last 120 days corroborates any acquisition approach, beyond the August 3 earnings 8-K filed under Item 2.02.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| TGTX | $8.3B | 20.1x | +55.9% |
| AXSM | $8.5B | 36.8x | +29.8% |
| AUPH | $2.2B | 15.6x | +43.8% |
| IOVA | $6.4B | n/a | +534.4% |
| KPTI | $7M | n/a | -94.8% |
| MDGL | $10.6B | 47.8x | +4.0% |
A Pattern Without a Disclosure
Acquisition speculation around TGTX has surfaced twice in roughly two months; similar rumors generated a standalone stock alert approximately 55 days before today. Recurring buyout noise without a company disclosure is a recognizable setup: short interest at 28.9% of the float means a credible bid, if one materialized, would trigger short-covering and amplify any move. TGTX has missed EPS consensus in each of its last four reported quarters, with the most recent shortfall at -88.9% below estimates, making the next earnings cycle the next real data point. Run the free TG Therapeutics, Inc. deep-dive to track what changes.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did TGTX stock surge today?
Buyout speculation has lifted TG Therapeutics to its best single-session gain in 3.5 months. The speculation comes on the heels of a five-year analysis showing BRIUMVI's 9.4% disability progression rate versus 17.9% for rival ofatumumab, giving a prospective acquirer concrete clinical data to underwrite.
Did TGTX insiders buy or sell stock recently?
Director Laurence N. Charney sold 5,000 shares at $54.96 on September 10, generating $274,800 in proceeds. Over the past 90 days, no TGTX insider has made a single open-market purchase.
Are there any SEC filings about an acquisition offer?
No SEC filing in the last 120 days corroborates any acquisition approach beyond the August 3 earnings 8-K. An executive acting on knowledge of imminent deal activity would face legal constraints on selling at market prices; Charney's open-market sale suggests he was not acting on such knowledge.
What percentage of TGTX shares are held short?
Short interest stands at 28.9% of the float with 74.7% institutional ownership. A credible acquisition bid could trigger a short-covering event and amplify any stock move.
What is TGTX's current financial performance?
Trailing revenue reached $800 million on 70.3% growth at 82.4% gross margins. However, TGTX has missed EPS consensus in each of its last four reported quarters, with the most recent shortfall at 88.9% below estimates.
TG Therapeutics stock is tracking for its best single-session gain in 3.5 months on fresh buyout speculation, arriving just days after a five-year clinical study showed BRIUMVI cut disability progression to roughly half the rate of a rival MS drug — yet the only Form 4 filed in the past 90 days records a director selling at open-market prices five weeks before the buzz returned.